Hackensack Meridian Joins 900-Patient Parkinson's Drug Trial Testing 2-Year Prasinezumab Infusions
Updated
Updated · Hackensack Meridian Health · May 19
Hackensack Meridian Joins 900-Patient Parkinson's Drug Trial Testing 2-Year Prasinezumab Infusions
1 articles · Updated · Hackensack Meridian Health · May 19
Hackensack Meridian Neuroscience Institute has joined the Phase III PARAISO study, which is testing whether Prasinezumab can slow Parkinson's disease progression rather than only ease symptoms.
The trial plans to enroll about 900 early-stage Parkinson's patients on stable levodopa doses and will compare monthly intravenous prasinezumab against placebo over 2 years.
Prasinezumab is an investigational antibody designed to target alpha-synuclein protein clumps, a hallmark of Parkinson's that researchers believe contributes to brain-cell death.
An optional second 2-year extension gives all participants the drug, as investigators pursue one of the field's few late-stage attempts at a disease-modifying Parkinson's therapy.
The study comes as Parkinson's remains the world's fastest-growing neurological disorder, with cases more than doubling from 1990 to 2015 and projected to double again by 2040.
Amidst stem cell and gene therapies, is this antibody our best shot at halting Parkinson's?
Why is Parkinson's disease spreading faster than any other neurological disorder in the world?
Can artificial intelligence diagnose Parkinson's years earlier just by listening to your voice?
PARAISO Phase III: A New Era in Parkinson’s Disease—Hackensack Meridian Health Joins Global Prasinezumab Trial
Overview
Hackensack Meridian Health has joined the PARAISO Phase III clinical trial, which is evaluating prasinezumab, a new drug that aims to slow the progression of Parkinson's disease. This is significant because current treatments only manage symptoms and there are no therapies that can actually slow or stop the disease. Experts at HMH describe this as a pivotal moment, bringing real hope to patients and the medical community. By participating in the PARAISO trial, HMH is helping to test a potential breakthrough therapy that could change the future of Parkinson's care.